Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial.
source https://www.sciencedaily.com/releases/2021/11/211108130903.htm
0 comments: